With the objective of establishing a Malaysian consensus on the use of topical NSAIDs in the management of musculoskeletal pain, this meeting brought together experts from various backgrounds, ie, rheumatology, pharmacy, orthopaedics and general medicine. At the meeting, Dr Mary Suma Cardosa delivered a talk on the pathophysiology and effective management of pain, while the lecture by Dr Yeap Swan Sim focused on the management of musculoskeletal and soft-tissue pain. This article presents excerpts from the expert meeting and features the consensus statements agreed during the meeting.
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Rheumatology digital copy today!
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.